Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart adjuvant therapy in stage IB lung adenocarcinoma
NCT06528847Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in lung adenocarcinoma, sponsored by Shanghai Pulmonary Hospital. Started Jun 2024; status: recruiting.
02
Drugs
benmelstobart
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06528847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528847.